Switching eczema treatment to ivarmacitinib
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests whether switching to a new oral medication (ivarmacitinib) helps people with moderate-to-severe eczema who still have symptoms even after using a standard injectable treatment (IL-4Rα inhibitor like dupilumab) for at least 12 weeks. It aims to see if the switch is effective and safe for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have moderate-to-severe atopic dermatitis (eczema).
- You have been on an IL-4Rα inhibitor (like dupilumab) for at least 12 weeks but still have significant symptoms.
- You have not taken other JAK inhibitors (including topical forms) in the last week.
- You do not have serious heart, liver, kidney, or other organ issues, or a history of blood clots or active infections like tuberculosis or hepatitis.
- You are not pregnant or breastfeeding (or you are willing to use birth control).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called Ivarmacitinib for people with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it helps reduce symptoms and improve skin condition.
This study tests an investigational drug (SIM0278) given as an injection to see if it helps reduce eczema symptoms. It is for people with moderate to severe atopic dermatitis who have not used certain other treatments recently.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study compares the effectiveness of a pill (upadacitinib) with several biologic injections (biologics are medicines that target specific parts of the immune system) in controlling moderate-to-severe atopic dermatitis (eczema). The goal is to see which treatment helps people achieve minimal disease activity, meaning their eczema is under good control.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.